Paul A. Beavis

Learn More
CD73 inhibits antitumor immunity through the activation of adenosine receptors expressed on multiple immune subsets. CD73 also enhances tumor metastasis, although the nature of the immune subsets and adenosine receptor subtypes involved in this process are largely unknown. In this study, we revealed that A2A/A2B receptor antagonists were effective in(More)
While breast cancer has not been considered a cancer amenable to immunotherapeutic approaches, recent studies have demonstrated evidence of significant immune cell infiltration via tumor-infiltrating lymphocytes in a subset of patient tumors. In this review we present the current evidence highlighting the clinical relevance and utility of tumor-infiltrating(More)
BET inhibitors (BETi) target bromodomain-containing proteins and are currently being evaluated as anti-cancer agents. We find that maximal therapeutic effects of BETi in a Myc-driven B cell lymphoma model required an intact host immune system. Genome-wide analysis of the BETi-induced transcriptional response identified the immune checkpoint ligand Cd274(More)
Targeting tumor elicited-immunosuppressive pathways has proven to be an efficient means of boosting antitumor immunity. The potential of this approach is underlined by the clinical success of monoclonal antibodies targeting cytotoxic T lymphocyte-associated protein 4 (CTLA4), programmed cell death 1 (PDCD1, best known as PD-1) and CD274 (best known as(More)
Infrastructure suppliers and operators, either government utilities or private enterprise, need to be involved in strategic freight processes at the urban scale. This is to ensure that infrastructure investment remains effective in facilitating whole network access and minimizing impacts in often congested and competitive networks. Infrastructure suppliers(More)
  • 1